Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...

PRESS RELEASEAB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...

In a groundbreaking development, First Ascent Biomedical unveils a compelling narrative of resilience and innovation through ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...

The House passed a bill last week that would “repurpose” $500 million meant for cleaning up environmental and safety hazards ...

In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.